Pulmonary fibrosis treatment OFEV (nintedanib) slows the progression of lung scarring, according to high-resolution scans used in a Phase 3b clinical trial. Computed tomography imaging demonstrated for the first time that six months of Ofev could reduce the progression of patients’ lung fibrosis lesions, compared with a placebo. Two…
News
The American Thoracic Society and Boehringer Ingelheim have established a two-year, $100,000 fellowship for idiopathic pulmonary fibrosis research. Pulmonary fibrosis is a group of lung diseases characterized by cough, shortness of breath, fatigue and low levels of oxygen in the blood. It involves the lungs becoming stiff and holding less air…
Esbriet (pirfenidone) seems to have diminishing therapeutic effect after six months of treatment and possibly no benefit after one year in idiopathic pulmonary fibrosis (IPF) patients with advanced disease, a Greek retrospective study shows. The study, “Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational…
Treatment with Esbriet (pirfenidone) reduces cough in patients with idiopathic pulmonary fibrosis (IPF), a new European study finds. The study, “Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis,” appeared in the European Respiratory Journal. Its senior author was Dr. Marlies Wijsenbeek of the respiratory…
A gene previously shown to be associated with cancer — called T-cell lymphoma invasion and metastasis 1 (TIAM1) — may be an effective therapeutic target in pulmonary fibrosis (PF), a new study from China suggests. The study reporting the findings, “TIAM1 inhibits lung fibroblast differentiation in pulmonary…
Children’s National Health System no longer treats just kids. Its Rare Disease Institute, launched in April 2017, has partnered with the National Organization for Rare Disorders (NORD) to become the first of many U.S. “centers of excellence” to look after patients with rare diseases, regardless of age. The effort…
A compound called tubastatin inhibits an enzyme-linked cell signaling pathway associated with lung tissue scarring, reducing pulmonary fibrosis, a study reports. The research on the HDAC6 enzyme in laboratory cell cultures and mice was able to identify only part of the mechanism involved in alleviating the scarring, however. The full…
Inhibiting an enzyme called phosphoglycerate dehydrogenase prevented additional lung tissue scarring in a mouse model of pulmonary fibrosis, a study reports. The discovery means scientists might be able to develop a PF therapy by targeting the enzyme, which is involved in metabolism, or transforming food into energy. The enzyme is…
The U.S. Food and Drug Administration has granted Fast Track designation to PBI-4050, ProMetic Life Sciences’ potential treatment for idiopathic pulmonary fibrosis, or IPF. Regulators recently approved ProMetic’s Investigational New Drug application for PBI-4050 and the company’s design for pivotal Phase 2/3 clinical trials of the therapy. A pivotal…
Ofev (nintedanib) is effective at slowing idiopathic pulmonary fibrosis (IPF) progression in patients over time regardless of their degree of lung function at the beginning of treatment, according to new results from an extension of a Phase 3 clinical trial. Ofev, by Boehringer Ingelheim, was approved by the U.S. Food and Drug…
